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INTRODUCTION 
By many estimates up to 40 percent of new chemical 
entities (NCEs) discovered by the pharmaceutical industry 
today are poorly soluble or lipophilic compounds. The 
solubility issues complicating the delivery of these new 
drugs also affect the delivery of many existing drugs. The 
ability to deliver poorly soluble drugs will grow in 
significance in the coming years as NCEs are relied upon 
for a larger share of the revenue within the pharmaceutical 
market by innovator companies. Similarly, generic drug 
manufacturers will need to employ economically efficient 
methods of delivery as more low solubility drugs go off 
patent, in order to maintain a competitive edge and 
sufficiently compete as profit margins shrink in this price-
sensitive industry. Relative to highly soluble compounds, 
low drug solubility often manifests itself in a host of in 
vivo consequences, including decreased bioavailability, 
These in vivo and in vitro characteristics and the 
difficulties in achieving predictable and reproducible in 
vivo/in vitro correlations are often sufficiently formidable 
to halt development on many newly synthesized 
compounds due to solubility issues. Relative to highly 
soluble compounds, low drug solubility often manifests 
itself in a host of in vivo consequences, including 
decreased bioavailability. Poorly soluble compounds also 
present many in vitro formulation obstacles, such as 
severely limited choices of delivery technologies and 
increasingly complex dissolution testing with limited or 
poor correlation to the in vivo absorption. These in vivo 
and in vitro characteristics and the difficulties in achieving 
predictable and reproducible in vivo/in vitro correlations 
are often sufficiently formidable to halt development on 
many newly synthesized compounds due to solubility 
issues. The Biopharmaceutical Classification System 
(BCS) groups poorly soluble compounds as Class II and 
IV drugs, compounds which feature poor solubility and 
high permeability, and poor solubility and poor 
permeability, respectively. Drug substances are considered 
highly soluble when the largest dose of a compound is 
soluble in <250mL water over a range of pH from 1.0 to 
7.5; highly permeable compounds are classified as those 
compounds that demonstrate >90 percent absorption of the 
administered dose (1). In contrast, compounds with 
solubility below 0.1 mg/mL, and often-even compounds 
with solubility below 10 mg/mL present difficulties related 
to solubilisation during formulation.1 
Cyclodextrins (CDs), with their ability to form molecular 
inclusion complexes with drug substances affect many of 
the physic chemical properties of the drugs without 
affecting their intrinsic lipophilicity or pharmacological 
properties  As a consequence of the inclusion 
process,many physicochemical properties, such as 
solubility, dissolution rate, stability, palatability, and 
bioavailability, can be favourably affected CDs are thus 
offering new hope to formulation scientists in their efforts 
to develop an effective drug delivery system. 
The number of applications of CDs in pharmaceutical 
formulations has been increasing in recent years because 
of their approval by various regulatory agencies However; 
the use of CDs in solid oral dosage forms is limited to low-
dose drugs with large stability constants because of the 
mass limitations of oral dosage units. 
 Cyclodextrins (CDs) improve solubility significantly they 
are still limited in their drug inclusion capacity and retain 
disadvantageous processing characteristics for oral dosage 
forms; the volume of CD complexes is often much greater 
than the volume of drug alone, which may severely limit 
the types of delivery technologies that may be employed.2 
CD complexes have also been employed in conjunction 
with hydrophilic polymers, such as hydroxylpropylmethyl 
cellulose, to improve the solubilising effect of the CDs. 
ABSTRACT 
Telmisartan (TLM) is an angiotensin II receptor antagonist used in the treatment of hypertension. According to BCS 
(biopharmaceutical classification system) Telmisartan belongs to class II drug, and it is practically insoluble in water and it 
shows low dissolution profile and poor absorption. The present study is to improve the solubility of Telmisartan by forming 
complexation with β- CD by using four convenient methods viz physical mixing method, kneading method, and solvent 
evaporation fusion method at different molar ratios of 1:1, dissolution studies were carried out in pH 7.4 phosphate buffer. The 
cyclodextrin complexes formulated by employing 1:1 (drug: complexing agent) with kneading technique showed higher drug 
release. 
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The improvement in solubilisation ability within these 
water-soluble polymer/drug included CD aggregates 
requires less cyclodextrin to solubilise the same amount of 
drug, reducing the volume constraints present for non 
aggregated CDs and increasing the range of delivery 
technologies available. 
 MATERIALS AND METHODS: 
Pure sample of Telmisartan was obtained from Medley 
Pharma limited, Daman. β-CD is purchased from SD Fine 
Chemicals Mumbai. 
Methods of preparation: 
1. Dry / Physical mixing: Some guests can be complexed 
by simply adding the guest to the CD and 
mixing/triturating them together. This works best with oils 
or liquid guests. 
2. Kneading Method:
 β - CD was mixed in glass mortar 
along with water to obtain a homogeneous paste. The drug 
was then slowly added to the paste and the mixture was 
triturated for 1 hr. during the process the water content was 
empirically adjusted to maintain the consistency of the 
paste. The paste formed was dried under vacuum for 24 
hours. Dried powder was passed through specific sieve no. 
and stored in a dessicator until further evaluation.3 
3. Solvent Method: Researchers often use hybrid fusion-
solvent method if thermal instability and immiscibility 
between the compound(s) and the carrier are present. In 
the process, the researchers first dissolve the compound in 
a small quantity of organic solvent and added to the molten 
carrier. Researchers then evaporate the solvent to generate 
the mass. They mill this mass to produce powder at desired 
particle size ranges. 
4. Fusion-melt Method: The fusion-melt involves melting 
the compound(s) and the carrier components together at 
temperatures at or above the melting point of all 
components. In the fusion process, researchers blend the 
compound and carrier in a suitable mixer. They heat, melt 
the blend and then cool the molten mixture rapidly to 
provide a congealed mass. They mill this mass to produce 
powders at desired particle size ranges 
Experimental Methods: 
Spectral and absorbance measurements by using UV –
Visible spectrophotometer by using,1-cm quartz cells. A 
simple UV spectrophotometric method was developed for 
the determination of Telmisartan in pure and its 
pharmaceutical formulations.  
Telmisartan exhibited maximum absorbance at 296 nm in 
Phosphate buffer (pH 7.4) Containing Sodium lauryl 
sulphate (0.2 %) and obeyed linearity in the concentration 
range of 1-10 µg/ml.  
Preparation of Stock Solution: 
Standard stock solution of Telmisartan was prepared by 
dissolving 10 mg of drug in 100 ml of Phosphate buffer 
(pH 7.4) Containing Sodium lauryl sulphate (0.2 %) in 100 
ml of volumetric flask to get a concentration of 10µg/ml. 
Preparation of Working Standard Solutions and 
construction of standard graph: 
To construct Beer’s law plot for Telmisartan, the stock 
solution was further used to prepare working standard 
solutions of concentrations ranging from 1 to 10 µg/ml 
different aliquots of working standard solutions of 
Telmisartan was transferred separately into a series of 10 
ml volumetric flasks and diluted to 10 ml using phosphate 
buffer .The absorbance were measured at λmax 296 nm 
against buffer as blank. The standard graph for Telmisartan 
was plotted by taking concentration of drug on x-axis and 
absorbance on y-axis and is shown in fig 1. The drug has 
obeyed Beer’s law in the concentration range of 1-10 
µg/ml.4 
Fourier Transforms Infrared (FTIR) spectroscopy. 
FTIR Spectroscopy was performed on Lab India by 
scanning the sample in zink seleniume (Znse). Before 
taking the spectrum of the sample, a blank spectrum of air 
background was taken. Number of scans, 24; resolution, 4 
cm−1; range, 500–4000cm−1 The sample of Pure Drug, 
and β- Cyclodextrin were scanned. The complexes of β-
CD with TEL prepared by different methods were scanned 
by FTIR ranges from 500-4000, There is no interaction 
between drug & beta CD. (Figure 5). 
Powder x-ray diffractromety: 
Powder x-ray diffraction patterns were recorded on X-Ray 
diffraction instrument (Philips Analytical X’Pert PRO) 
with Cu radiation, at a voltage of 45kV and current of 
40mA. The scanning speed was Gonio between 5 and 
40theta. diffraction angle (2θ) range.  
RESULT & DISCUSSION: 
The linear relationship between the concentration of 
Telmisartan and the corresponding absorbance values was 
shown by- Y = 0.055 X + 0.011 Where, Y = absorbance, 
and X = concentration of Telmisartan (µg/ml) A positive 
correlation between the concentration of Telmisartan and 
the corresponding absorbance values was observed 
(correlation coefficient, r2 = 0.993). The amount of 
Telmisartan in either the β-CD complex or the dissolution 
fluids was calculated using the linear relationship as given 
above or directly from the standard graph as shown in fig 
1. 
Preparation of solid complexes 
Complexes of β-CD with TEL were prepared in the molar 
ratio of 1:1(on the basis of phase solubility study) by 
different methods like Physical mixing, Kneading, Solvent 
evaporation, and Fusion method.). 
Physical Mixture: 
 Physical mixture was prepared by triturating TEL and β-
CD together for 30 min in a clean and dry glass mortar 
until a homogeneous mixture was obtained. And then was 
forced through sieve no 100. 
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Figure 1: Standard curve for the estimation of Telmisartan in phosphate buffer pH 7.4 
Kneading Method: 
 β-CD mixed in glass mortar along with water to obtain a 
homogeneous paste. The drug (either in powder form or as 
solution with minimum quantity of methanol) was then 
slowly added to the paste and the mixture was triturated 
for 1 hr. during the process the water content was 
empirically adjusted to maintain the consistency of the 
paste. Methanol was added to assist dissolution of TEL 
during the process. The paste was dried at room temp., 
pulverized and forced through sieve no 100.5 
Fusion Method: 
TEL and β-CD were thoroughly mixed and placed in a 
sealed container with a small amount of water. The 
contents are heated to about 1000C and then removed and 
dried. The mass was then pulverized and forced through 
sieve no 100. 
Solvent evaporation Method:7,8 
 A solution of Telmisartan in methanol was gradually 
added to equi-molar concentration of β-CD in water and 
agitated at 500C for 30 min and toward the end of addition 
turbidity developed in the mixture. At the end of this 
period the solution was filtered, and the moist solid was 
kept in oven 500C for removal of last trace of solvent. The 
mass was then pulverized and passed through sieve no 
100. 
 
Table 1: Preparation of Telmisartan & β-CD solid dispersions by different technique 
Type of formulation TEL:β-CD (molar ratio) Solid dispersion Method Media 
TPM 1:1 Physical Mixing …….. 
TKW 1:1 Kneading Water 
TKM 1:1 Kneading Methanol + Water 
TSE 1:1 Solvent Evaporation Methanol + Water 
TFW 1:1 Fusion Water 
  
Table 2: Drug content of Tel β-CD complexes (% Drug content) 
Formulation Theoretical drug content in 100mg Practical drug content in 100mg (mean n=3) % Drug content 
TPM 27.64 27.02 97.75 
TKW 27.64 26.93 97.43 
TKM 27.64 27.12 98.12 
TSE 27.64 27.08 97.98 
TFU 27.64 27.11 98.08 
 
Saturation solubility of different formulations of 
Telmisartan. 
The saturation solubility of pure TEL and its complexes 
with β -CD is shown in table 3. The saturation solubility of 
pure TEL is 11.9µg/ml while the saturation solubility of all 
other complex prepared by various methods exhibited 
dramatic increase in the saturation solubility. TPM and β -
CD (complex prepared by physical mixing) showed a 
lower value for saturation solubility than that of other 
complexes, the low saturation solubility can be attributed 
to poor complexation efficiency during physical mixing. 
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Fourier Transforms Infrared (FTIR) spectroscopy. 
FTIR spectra of TEL and β – CD its Complex are 
presented In (Figure 5). Pure Telmisartan spectra showed 
sharp characteristic peaks at  3746, 2958, 1693, 1456 and 
1266 cm-1 All the above characteristic peaks appears in 
the spectra of all Complex  at same wavenumber indicating 
no modification or interaction between the drug and β – 
CD.  . 
Powder x-ray diffractromety: 
Powder x-ray diffraction (XRD) of Pure Drug & β – CD 
with complex show in (Figure 8.) The X- ray 
diffractogram of Telmisartan has sharp peak at different 
angle (2θ) 6.72 θ, 14.17 θ, 18.97 θ, 22.18 θ, 25.85θ  show a 
tripical crystalline pattern. However, all major 
characteristic crystalline peaks appear in the diffractogram 
of both physical mixtures and solid dispersion system. 
Moreover, the relative intensity and 2θ angle of these 
peaks remains practically unchanged. Thus it can be 
clearly suggestive from X-ray data that there is no 
amorphization of TEL. and it is still in its original 
crystalline form.  
Characterization of complexation: 
 
Table: 3. Saturation solubility of different formulations 
of Telmisartan. 
Formulation Saturation solubility of Telmisartan 
Pure TEL 11.95 ± 0.84 
TPM 78.90 ± 2.11 
TKW 135.78 ± 2.31 
TKM 141.47 ± 2.67 
TSE 104.99 ± 2.67 
TFU 119.82 ± 2.48 
 
 
Figure 2: Saturation solubility of Telmisartan
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Figure 3: FTIR spectrum of pure Drug Telmisartan 
 
 
 
 
 
 
 
 
 
 
Figure 4: FTIR spectrum of pure β - cyclodextrin. 
 
94
95
Tr
an
sm
itt
an
ce
[%
]
96
97
98
99
10
0
37
44
.90
32
42
.19
28
99
.79
23
62
.26
16
46
.46
15
16
.21
14
14
.51
13
33
.42
11
51
.53
10
23
.17
93
9.1
7
85
4.6
1
75
2.9
3
69
8.5
7
57
4.3
0
500100015002000250030003500
Wavenumber cm-1
Rakesh et al                                     Journal of Drug Delivery & Therapeutics; 2013, 3(2), 74-79   78 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
50
Tr
an
sm
itt
an
ce
[%
]
60
70
80
90
10
0
37
38
.4
8
30
55
.0
4
29
55
.7
5
28
66
.0
4
24
60
.1
3
19
07
.4
4
16
93
.3
7
16
04
.3
3
14
54
.8
6
13
82
.4
6
13
04
.7
2
12
65
.5
4
11
26
.4
7
10
15
.3
4
92
2.
83
86
2.
07
80
8.
44
74
8.
14
70
4.
03
66
8.
38
61
0.
73
57
7.
36
54
7.
42
500100015002000250030003500
Wavenumber cm-1
 
Figure 5: FTIR Spectrum of mixture of  (TEL& β--CD) 
 
 
Figure 6: x-ray diffractromety of Pure Telmisartan.. 
 
Figure 7: x-ray diffractromety of β - CD 
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Figure 8: x-ray diffractromety of Mixture Tel + β - CD. 
CONCLUSION 
Solid dispersions of Telmisartan were prepared by 
Different technique of solid dispersion method using 
carrier’s β - CD. In the present work total five formulations 
were prepared by using Telmisartan with β - CD by using 
five convenient methods viz physical mixing method, 
kneading method, and solvent evaporation fusion method 
at different molar ratios of 1:1, dissolution studies were 
carried out in pH 7.4 phosphate buffer. The cyclodextrin 
complexes formulated by employing 1:1 (drug: 
complexing agent) with kneading technique showed higher 
drug release.9, 10 
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